Skip to content

Evaluation of the effect of letrozole on symptomatic uterine leiomyomas

Evaluation of the effect of letrozole on symptomatic uterine leiomyomas

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201102015444N2
Enrollment
30
Registered
2011-02-24
Start date
2009-08-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Liomyoma. Noninflammatory disorder of uterus, unspecified

Interventions

Letrozole tablet, 2/5 mg, daily for 90 days.
Treatment - Drugs
Letrozole tablet, 2/5 mg, daily for 90 days

Sponsors

Vice chancellor for Research of Kashan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 51 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : pre menopause patients who have symptomatic liomyomatos equivalent or larger than 3 cm. Exclusion criteria: patients who have received hormonal therapy; patients who have severe medical disorders; patients who have surgical treatment of myoma.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Uterine leiomyomas size. Timepoint: before &90 days after 90 days treatment. Method of measurement: sonography.;Uterine size. Timepoint: before &90 days after 90 days treatment. Method of measurement: sonography.

Secondary

MeasureTime frame
FSH-LH. Timepoint: before & after 90 days treatment. Method of measurement: blood sampling.;Stradiol. Timepoint: before & after 90 days treatment. Method of measurement: blood sampling.;Ferritine. Timepoint: before & after 90 days treatment. Method of measurement: blood sampling.;Patients symptoms. Timepoint: before & after 90 days treatment. Method of measurement: questionnaire.;Hemoglobin. Timepoint: before & after 90 days treatment. Method of measurement: blood sampling.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mansoureh Samimi

Kashan University of Medical sciences

samimi_m@kaums.ac.ir+98 36 1446 0180

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026